Benitec Biopharma Inc. announced financial results for the fiscal quarter ended December 31, 2025, reporting a net loss of $11.8 million. The company highlighted positive clinical data from its BB-301 Phase 1b/2a study, noting all four Cohort 1 completers were formal responders, and reported holding $189 million in cash and cash equivalents.
Key takeaways
Net loss for the quarter ended December 31, 2025 was $11.8 million, or $(0.26) per basic and diluted share.
All four patients enrolled in Cohort 1 of the BB-301 Phase 1b/2a treatment study were formal Responders at the 12-month follow-up.
Cash and cash equivalents totaled $189 million as of December 31, 2025.
Total operating expenses increased to $13.4 million for the quarter, up from $10.8 million in the same quarter of the prior year.
The Company plans to engage with the FDA in mid-2026 to confirm the BB-301 pivotal study design.
BB-301 received Fast Track Designation from the FDA in November 2025.